A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
NCT07258836
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to check how safe and well-tolerated [18F]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Neoplasms
- Healthy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- August 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- Ichor Research · Syracuse, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.